Literature DB >> 19009370

Curative stereotactic body radiotherapy for liver malignancy.

Peter Gunvén1, Henric Blomgren, Ingmar Lax, Seymour H Levitt.   

Abstract

Nine patients with 11 primary or secondary liver non-neuroendocrine malignancies with mean and maximum diameters of 4.0 and 7.7 cm became long-term survivors after precision irradiation in a stereotactic body frame. Doses varied from 20 to 45 Gy split at 2-4 occasions a few days apart, with higher doses in the target centers. Occasional chemotherapy was stopped well before irradiation. No hospitalizations were needed because side effects, regional pain and nausea, were mild. All patients have now survived 5-14 years without recurrences. Two verified and one suspected secondary cancers occurred in organs close to the irradiated targets, and two of them could be resected for cure. Precision irradiation can thus cure selected liver malignancies. It is the first non-invasive method to achieve this, and the present patients are its first long-term survivors. A prolonged follow-up period is, however, necessary, because we have in other patients seen local tumor regrowth as late as four years after irradiation. The approach may cure some tumors, which are technically unsuited for other treatment modalities, and can be used for patients at high surgical risk. The success rate for local control seems good, but has to be defined by formal studies after optimization of radiation doses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009370     DOI: 10.1007/s12032-008-9125-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

Review 1.  Partial volume tolerance of the liver to radiation.

Authors:  Laura A Dawson; Randall K Ten Haken
Journal:  Semin Radiat Oncol       Date:  2005-10       Impact factor: 5.934

2.  Radiofrequency ablation of liver tumors: influence of technique and tumor size.

Authors:  Boris W Kuvshinoff; David M Ota
Journal:  Surgery       Date:  2002-10       Impact factor: 3.982

3.  Hepatocellular carcinoma among atomic bomb survivors: significant interaction of radiation with hepatitis C virus infections.

Authors:  Gerald B Sharp; Terumi Mizuno; John B Cologne; Toshiyuki Fukuhara; Saeko Fujiwara; Shoji Tokuoka; Kiyohiko Mabuchi
Journal:  Int J Cancer       Date:  2003-02-10       Impact factor: 7.396

4.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 5.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07

Review 6.  Surgical therapy of liver metastases.

Authors:  Boris Kuvshinoff; Yuman Fong
Journal:  Semin Oncol       Date:  2007-06       Impact factor: 4.929

7.  Hepatic resection with reconstruction of the inferior vena cava or hepatic venous confluence for metastatic liver tumor from colorectal cancer.

Authors:  Taku Aoki; Yasuhiko Sugawara; Hiroshi Imamura; Yasuji Seyama; Masami Minagawa; Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Am Coll Surg       Date:  2004-03       Impact factor: 6.113

8.  Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study.

Authors:  Tito Livraghi; Luigi Solbiati; M Franca Meloni; G Scott Gazelle; Elkan F Halpern; S Nahum Goldberg
Journal:  Radiology       Date:  2003-02       Impact factor: 11.105

9.  Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases.

Authors:  David A Kooby; Jennifer Stockman; Leah Ben-Porat; Mithat Gonen; William R Jarnagin; Ronald P Dematteo; Scott Tuorto; David Wuest; Leslie H Blumgart; Yuman Fong
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

10.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Lawrence E Harrison; Baburao Koneru; Phil Baramipour; Adrian Fisher; Alison Barone; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Daniel Contractor; Maria Korogodsky
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  4 in total

Review 1.  Review and uses of stereotactic body radiation therapy for oligometastases.

Authors:  Filippo Alongi; Stefano Arcangeli; Andrea Riccardo Filippi; Umberto Ricardi; Marta Scorsetti
Journal:  Oncologist       Date:  2012-06-20

Review 2.  Stereotactic body radiation therapy: a novel treatment modality.

Authors:  Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

3.  Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors.

Authors:  Peter Gunvén; Eduard Jonas; Henric Blomgren; Eva Rutkowska; Kristin Karlsson; Ingmar Lax; Seymour Levitt
Journal:  Med Oncol       Date:  2010-05-19       Impact factor: 3.064

4.  Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer.

Authors:  Daniel W Kim; Grace Lee; Hwan Lee; Jack M Qian; Nina N Sanford; Miranda B Lam; Naeem Tahir; Harvey J Mamon
Journal:  Adv Radiat Oncol       Date:  2019-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.